Heat shock protein 90 (HSP90) is considered a very attractive drug-target for cancer therapy, since most of its client proteins play key roles in the acquisition and/or maintenance of the malignant phenotype [1]–[4]. The gene discussed is HSP90AA1; the disease is cancer.